Wogonin Influences Osteosarcoma Stem Cell Stemness Through ROS-dependent Signaling

HYEBIN KOH1*, HU-NAN SUN2*, ZHEN XING3, REN LIU3, NISANSALA CHANDIMALI3, TAEHO KWON4 and DONG-SUN LEE3,5,6,7

1Department of Animal Biotechnology, Jeju National University, Jeju, Republic of Korea; 2College of Life Science and Biotechnology, Heilongjiang Bayi Agricultural University, Daqing, P.R. China; 3Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, Republic of Korea; 4Primate Resources Center, Korea Research Institute of Bioscience and Biotechnology, Jeonbuk, Republic of Korea; 5Subtropical/Tropical Organism Gene Bank, Jeju National University, Jeju, Republic of Korea; 6Faculty of Biotechnology, College of Applied Life Sciences, Jeju National University, Jeju, Republic of Korea; 7Practical Translational Research Center, Jeju National University, Jeju, Republic of Korea

Abstract. Background/Aim: Wogonin, a flavonoid-like compound extracted from the root of Scutellaria baicalensis Georgi, has been shown to have anticancer effects against cancer cells. Osteosarcoma is the most malignant type of bone cancer and can appear in any bone, with a high propensity for relapse and metastasis. The present study aimed to assess the anticancer effects of wogonin on osteosarcoma stem cells. Materials and Methods: The cytotoxic effects of wogonin on CD133+ Cal72 osteosarcoma stem cells were assessed through in vitro experiments by MTT assay, transwell assay, sphere-formation assay, flow cytometry, immunocytochemistry and western blotting. Results: Wogonin suppressed stem cell characteristics and the expression of stem cell-related genes by regulating reactive oxygen species (ROS) levels and ROS-related signaling of CD133+ Cal72 cells, effects which were reversed by ROS scavenger N-acetylcysteine. Conclusion: Wogonin may be a promising candidate for successful clinical management of osteosarcoma by regulating ROS-related mechanisms and stem cell-related genes.

This article is freely accessible online.

*These Authors contributed equally to this study.

Correspondence to: Professor Dong-Sun Lee, Department of Biotechnology, College of Applied Life Science, Jeju National University, Jeju, Republic of Korea. Tel: +82 647543340, e-mail: dongsunlee@jejunu.ac.kr

Key Words: Wogonin, osteosarcoma, cancer stem cells, ROS, stemness.

Osteosarcoma, the most common type of malignant bone tumor, is most prevalent among children and adolescents and accounts for 2.4% of pediatric cancer cases (1). It is most common among the ages of 10-16 years and the second most common among those aged over 40 years. The tumor is potentially present in bone marrow and then may grow into a mass of tumors and can occur in any bone (2). At present, the first-line treatment for most osteosarcoma involves surgery with intensive adjuvant chemotherapy (3). However, many patients still have poor survival due to relapse and metastasis of osteosarcoma (4).

Cancer stem cells (CSCs) are cancer cells that have characteristics related to stem cells, such as self-renewal and differentiation abilities (5). Expression of CSC genes is known to induce cancer metastasis (6). In particular, it was reported that osteosarcoma stem cells have a high capacity for tumor metastasis (2). A pentaspan membrane glycoprotein, CD133, is one of the most well-known biomarkers used for the detection of CSCs. It plays an important role in tumor growth, metastasis, tumorigenesis and tumor relapse (7). Finding a drug candidate involved in down-regulating the expression of genes related to osteosarcoma stem cell behaviour is an urgent need.

Reactive oxygen species (ROS) are forms of active oxygen and result from cellular metabolism (8). Some studies have revealed that an increased ROS level reduces the expression of stemness-related genes in CSCs and this effect can be reversed by ROS scavengers such as N-acetylcysteine (NAC) (9, 10).

Wogonin (5,7-dihydroxy-8-methoxyflavone) is a flavonoid-like compound that extracted from the root of Scutellaria baicalensis Georgi (Figure 1A) (11). It is well-known for diverse biological effects such as anti-
inflammatory, antioxidant and anticancer effects of various cell types such as non-small cell lung cancer, prostate cancer and ovarian cancer. Furthermore, according to some recent studies, wogonin may be a candidate anticancer drug, with the virtue of inducing selective apoptosis in cancer cells (12). Recently, we showed that wogonin has inhibitory effects on metastasis of cancer by down-regulating the expression of matrix metalloproteinase 9 in osteosarcoma stem cell (13). However, the regulatory mechanism underlying the effects of wogonin on osteosarcoma stem cell stemness is not yet understood.

In this study, we observed the effects of wogonin on the stemness of osteosarcoma stem cells and investigated the possible mechanisms involved in CD133+ Cal72 cells.

Materials and Methods

Reagents. Wogonin (98% of purity by high-performance liquid chromatography) was purchased from Sigma-Aldrich (St. Louis, MO, USA), dissolved in dimethyl sulfoxide (DMSO) and stored at −20°C.

Cell culture and treatments. CD133+ Cal72 cells (Gibco, ThermoFisher Scientific, Waltham, MA, USA) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 1% penicillin (Invitrogen) supplemented with 10 ng/ml human epidermal growth factor (hEGF; Calbiochem, Kenilworth, NJ, USA) and 20 ng/ml basic fibroblast growth factor (bFGF; KOMA Biotech, Seoul, Republic of Korea). The cells were maintained in an incubator at 37°C with 5% CO2. In further experiments, CD133+ Cal72 cells were pre-treated for 1 h with 5 μM N-acetylcycteine (NAC) (Sigma, St. Louis, MO, USA) prior to exposure to 0, 20, 40 and 80 μM wogonin for 24 h.

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) for cytotoxicity and cell proliferation assay. CD133+ Cal72 cells were seeded at a density of 1×10^4 cells/well in 96-well plates and incubated for 24 h before treatment. Cells were treated with wogonin with or without pre-treatment with 5 μM NAC for 1 h in DMEM containing 1% FBS for cytotoxicity assay, or 0.5% FBS for 24 h for cell proliferation assay. EZ-Cytox (Dogenbio, Seoul, Republic of Korea) was added to each well, and the plates were incubated for 1 h at 37°C. The optical density (OD) was then measured using a scanning multi-well spectrophotometer at a wavelength of 450 nm.

Western blotting. Lysates from CD133+ Cal72 cells treated with wogonin with or without NAC were collected in RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 50 mM Tris, pH 8.0, and a protease inhibitor cocktail). From each sample, 30 μg was loaded on a gel for sodium dodecyl sulfate-polyacrylamide gel electrophoresis and run in 1X Tris Glycine (T&I, Chuncheon, Republic of Korea). The proteins were transferred onto nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). Western blot was performed with rabbit or mouse antibodies against survivin (Abcam, Cambridge, MA, USA), CD133 (Boster Bio, Pleasanton, CA, USA), octamer-binding transcription factor 3/4 (Oct3/4) (Santa Cruz Biotechnology, Dallas, TX, USA), protein kinase B (AKT) (Boster Bio, Pleasanton, CA, USA), p-akinase-3-phospho-AKT (p-AKT), extracellular signal-regulated kinase (ERK), p-ERK, signal transducer and activator of transcription 3 (STAT3), p-STAT3, peroxiredoxin 2 (PRX2), PRX3, PRX5 (AbFrontier, Seoul, Republic of Korea), NOTCH1 (Cell Signaling Technology, Danvers, MA, USA), and MYC (Bioss, Woburn, MA, USA). Specific binding was detected using a Super Signal chemiluminescent substrate (ThermoFisher Scientific), according to the manufacturer’s instructions.

Immunocytochemistry assay for stemness marker CD133. CD133+ Cal72 cells were seeded at a density of 5×10^4 cells/well in 4-well plates in growth medium and treated with wogonin (0, 20, 40, 80 μM) for 24 h. The cells were fixed in 3.7% paraformaldehyde for 10 min and incubated in blocking solution (1% bovine serum albumin) for 1 h at room temperature. The cells were incubated with primary antibodies against CD133 diluted in blocking buffer overnight at 4°C and then stained by a fluorescent secondary antibody, goat anti-rabbit IgG (Santa Cruz Biotechnology) with phycoerythrin for 2 h at room temperature. Nuclei were stained for 15 min with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine. Images were captured under an inverted microscope.

ROS detection with 2’,7’-dichlorofluorescin diacetate (DCF-DA). CD133+ Cal72 cells were seeded in 6-well plates in growth medium and treated with wogonin (0, 20, 40, 80 μM) with or without 5 mM NAC. After 24 h, cells were incubated with 20 μM DCF-DA in a dish at 37°C for 20 min then fluorescence imaging and flow cytometry (BD Biosciences, San Jose, CA, USA) were performed.

Sphere-formation assay. CD133+ Cal72 cells were seeded at 2×10^3 cells/well in 6-well Ultra Low Cluster plates (Corning, New York City, NY, USA). The cells were cultured with DMEM/F12 (Invitrogen) containing 2% B27 supplement (Invitrogen), 10 ng/ml hEGF, 20 ng/ml basic fibroblast growth factor (bFGF), and 1% antibiotics, and treated with wogonin (0, 20, 40, 80 μM) with or without 5 mM NAC for 7 days (10, 14). The size of spheres was estimated under a microscope.

Wound-healing assay. CD133+ Cal72 cells were seeded at 5×10^4 cells/well in 96-well plates and incubated for 24 h and allowed to grow to 98-100% confluence. Using a wound maker (Essen Bioscience, Ann Arbor, MI, USA), a linear scratch was made in the cell layer (10, 14). Cells were washed with 1X phosphate-buffered saline and DMEM containing wogonin (0, 20, 40, 80 μM) and 0.5% FBS was added. Photomicrographs were taken of the migrated cells at 0 and 24 h using the IncuCyte Live-Cell Analysis System (Essen Bioscience).

Transwell migration and Matrigel invasion assays. In vitro migration and invasion assays were performed using transwell 24-well chambers (pore size 8 μm; Merck Millipore, Darmstadt, Germany) without (migration) or with (invasion) Matrigel. Briefly, 150 μl of CD133+ Cal72 cell suspensions (1×10^5 cells/well) were treated with wogonin (0, 20, 40, 80 μM) in DMEM containing 0.5% FBS and seeded separately into the upper chambers; the lower chamber well contained 750 μl of DMEM containing wogonin (0, 20, 40, 80 μM) and 0.5% FBS was added. Cells were then incubated for 48 h at 37°C and with 5% CO2. Non-invasing cells were then removed from the upper chamber, while invading cells were fixed with 3.7% paraformaldehyde and stained with 0.1% crystal violet. The cell count was performed under a microscope (10, 14).
Data analysis. Statistical analyses were performed using SPSSv.20.0.1 software (IBM, Armonk, NY, USA). Experimental differences among treatment groups with values of \( p < 0.05 \) were considered statistically significant for the cell viability assay.

**Results**

Wogonin reduced cell viability and proliferation of CD133+ Cal72 cells. To confirm the cytotoxic effects of wogonin, cytotoxicity and proliferation MTT assays were performed after wogonin treatment \((0, 20, 40, 80 \, \mu M)\) of CD133+ Cal72 cells. The results showed that wogonin treatment significantly reduced cell viability (Figure 1B) and inhibited CD133+ Cal72 cell growth (Figure 1C). Furthermore, western blotting showed that wogonin treatment significantly down-regulated the protein expression of survivin, which is inhibitor of apoptotic activation (Figure 1D). These data indicate that wogonin was cytotoxic and suppressed cell proliferation of CD133+ Cal72 cells most likely by inducing cell death.

Wogonin reduced the stemness, migration, and self-renewal ability of CD133+ Cal72 cell. To determine whether wogonin affected the self-renewal ability of CD133+ Cal72 cells, sphere-formation assays were performed. As shown in Figure 2A, the size of spheres was reduced in a dose-dependent manner, indicating that self-renewal of CD133+ Cal72 cells was inhibited by wogonin treatment. Wound-healing assay revealed that wogonin suppressed metastasis as observed by the lower restoration of scratches (Figure 2B). Transwell assays showed that wogonin treatment also reduced the migratory and invasive capacities of CD133+ Cal72 cells (Figure 2C and D).

Furthermore, the expression of several cancer stem cell markers was assessed after wogonin treatment. The results showed that stem cell markers CD133 and OCT3/4 were significantly down-regulated by wogonin treatment in a dose-dependent manner (Figure 2E). The down-regulation of CD133 expression was also confirmed by immunocytochemistry. The results revealed that wogonin dramatically reduced the expression of CD133 compared to control cells (Figure 2F).
Taken together, these findings show that wogonin suppressed CD133+ Cal72 cell stemness by inhibiting cell migration, invasion and sphere formation, as well as the expression of cancer stem cell surface markers.

Effect of wogonin on cellular ROS level and ROS-dependent signaling in CD133+ Cal72 cells. To clarify the effect of wogonin on cellular ROS level and signaling related to ROS, CD133+ Cal72 cells were treated with wogonin (0, 20, 40 and 80 μM). The cellular ROS level was detected by DCF-DA staining and measured by flow cytometry (Figure 3A) and fluorescence microscopy (Figure 3B). The results showed that wogonin treatment significantly increased the cellular ROS level in a dose-dependent manner, being greatest at 80 μM. Furthermore, we also examined the protein expression level of peroxiredoxins, a family of antioxidant enzymes reported to be essential in scavenging intracellular ROS (14, 15). The results showed that wogonin treatment affected the protein expression of PRX family members, especially by down-regulating PRX5, which can efficiently eliminate ROS in cytosol and mitochondria (16), while not markedly affecting PRX2 and PRX3 in CD133+ Cal72 cells (Figure 3C).

The ROS-dependent signaling pathways (17) were also examined after wogonin treatment. As shown Figure 3D, wogonin treatment significantly inhibited the phosphorylation of AKT and STAT3, as well as NOTCH1 protein expression, while up-regulating ERK phosphorylation in CD133+ Cal72 cells. Together, these data suggest that wogonin induces cellular ROS and regulates ROS-dependent signaling in CD133+ Cal72 cells.

ROS was involved in wogonin-induced efforts on stemness in CD133+ Cal72 cell. NAC is an efficient cellular ROS scavenger (18). To clarify the effect of ROS on wogonin-induced reduction of cell proliferation, CD133+ Cal72 cells were pre-treated with 5 mM of NAC followed by wogonin treatment. As shown in Figure 4A, NAC pre-treatment significantly abrogated wogonin-induced inhibition of cell proliferation and also reversed the wogonin-induced reduction of gene expression related to cancer stem cells (2020).
accumulation of cellular ROS in CD133+ Cal72 cells (Figure 4B). Furthermore, the effect of NAC treatment on single cell sphere-forming ability was assessed. As shown in Figure 4C, NAC treatment significantly restored sphere-forming ability which was inhibited by wogonin treatment in a dose-dependent manner. We also examined the effect of NAC treatment on MYC and STAT3 phosphorylation, which are reported closely related to the maintenance of stem cell stemness. As shown in Figure 4D, NAC treatment dramatically reversed the down-regulation of MYC and STAT3 phosphorylation level induced by wogonin. These data show ROS is associated with the effects of wogonin on stemness in CD133+ Cal72 cells. NAC suppression of ROS restored stemness and the ability for self-renewal.

Discussion

CSC properties have been reported in numerous types of tumors and are considered to be the cause of tumor initiation, self-renewal, resistance to tumor therapeutics, and metastasis (19). In this study, we describe the cytotoxic activity of wogonin, which is a phytochemical extracted from the root of *S. baicalensis* Georgi. Wogonin may be helpful for patients with osteosarcoma by inducing ROS and osteosarcoma stem cell death. The analysis of *in vitro* experiments suggests that wogonin increases the ROS level in cells and inhibits stemness by regulating ROS-related signaling in osteosarcoma stem cells.

Peroxiredoxins have the ability to protect sensitive proteins from oxidative damage from ROS (20). PRXs are classified
as PRX1-6 according to their intracellular region. PRX5 in particular, located within mitochondria, can effectively remove ROS generated in the mitochondria (21). In the present study, we showed that wogonin down-regulated the expression of PRX5 on CD133+ Cal72 cells and induced ROS. The results indicate that PRX5 appears to be a key player in ROS production in osteosarcoma stem cells.

STAT3 is transcription factor that involved in growth and metastasis in several types of cancer cell (22, 23). STAT3 is highly expressed in osteosarcoma and may be a key molecular target for developing drugs for human osteosarcoma (24). Furthermore, some studies already showed that the inhibition of STAT3 led to ROS generation in human osteosarcoma cells (25). In addition, it has been reported that activation of ERK signaling is regulated by ROS

and PRX5 knockdown up-regulated ERK activation related to activation of dynamin-related protein 1 (26). Our results suggest that wogonin down-regulates the expression of PRX5 and activates ERK signaling by increasing the ROS level.

It has been reported that MYC and OCT3/4, stem cell-related genes, have been used to induce the differentiation of osteosarcoma stem cells (27). CD133, a CSC marker, plays a pivotal role in tumor growth, metastasis, tumorigenesis and relapse of cancer (7). It is expected that the reduction of stemness-related genes, especially of CD133, may be a key treatment method for the elimination of CSCs. In this study, we showed that the expression of stemness-related genes was reduced by wogonin treatment.

In conclusion, our study suggests that wogonin is cytotoxic to osteosarcoma cells via suppressing stemness by
regulating ROS-related signaling. Although no in vivo study was performed here, our in vitro results provide evidence that wogonin may be a promising candidate for osteosarcoma therapy, increasing our understanding of the mechanisms associated with wogonin effects on ROS, especially with respect to its effects on stemness.

Conflicts of Interest

The Authors declare no conflicts of interest.

Authors’ Contributions

Hyehin Koh and Hu-Nan Sun designed and performed all the experiments. Zhen Xing, Ren Liu, and Nisansala Chandimiali performed the data analysis. Taeho Kwon, Jong-Hee Lee, Sun-Uk Kim performed the data analysis. Dong-Sun Lee supervised the study. All Authors read and approved the final article.

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2016R1A6A1A03012862) and by the project for Cooperative Research Program for Agriculture Science and Technology Development (PJ01316701) Rural Development Administration, Republic of Korea.

References

1. Sakthikumar S, Elvers I, Kim J, Arendt ML, Thomas R, Turner-Maier J, Swofford R, Johnson J, Schumacher SE, Alfoldi J, Axelsson E, Couto CG, Kisseberth WC, Pettersson ME, Getz G, Meadows JRS, Modiano JF; Breen M, Kierczak M, Forsberg-Nilsson K, Marinescu VD and Lindblad-Toh K: Setd2 is recurrently mutated in whole-exome sequenced canine osteosarcoma. Cancer Res 78(13): 3421-3431, 2018. PMID: 29724721. DOI: 10.1158/0008-5472.CAN-17-3558

2. Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, Gonzalez MV, Baldini N, Garcia-Castro J and Rodriguez R: Osteosarcoma: Cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int 2016: 3631764, 2016. PMID: 27366153. DOI: 10.1155/2016/3631764

3. Kansara M, Teng MW, Smyth MJ and Thomas DM: Cancer stem cells and clinical applications. Cancer Sci 108(3): 283-289, 2017. PMID: 28064442. DOI: 10.1111/cas.13155

4. Ji Q, Xu X, Song Q, Xu Y, Tai Y, Goodman SB, Bi W, Xu M, Jiao S, Maloney WJ and Wang Y: miR-223-3p inhibits human osteosarcoma metastasis and progression by directly targeting CDH6. Mol Ther 26(5): 1299-1312, 2018. PMID: 29628305. DOI: 10.1016/j.therap.2018.03.009

5. Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T and Okamoto T: Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications. Cancer Sci 108(3): 283-289, 2017. PMID: 28064442. DOI: 10.1111/cas.13155

6. Shiozawa Y, Nie B, Pienta KJ, Morgan TM and Taichman RS: Cancer stem cells and their role in metastasis. Pharmacol Ther 138(2): 285-293, 2013. PMID: 23384596. DOI: 10.1016/j.pharmthera.2013.01.014

7. Jang JW, Song Y, Kim SH, Kim J and Seo HR: Potential mechanisms of CD133 in cancer stem cells. Life Sci 18: 25-29, 2017. PMID: 28697984. DOI: 10.1016/j.lfs.2017.07.008

8. Huang K, Chen Y, Zhang R, Wu Y, Ma Y, Fang X and Shen S: Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo. Cell Death Dis 9(2): 157, 2018. PMID: 29410403. DOI: 10.1038/s41419-017-0166-5

9. Son YW, Cheon MG, Kim Y and Jang HH: PRX2 links ROS homeostasis to stemness of cancer stem cells. Free Radic Biol Med 134: 260-267, 2019. PMID: 30611866. DOI: 10.1016/j.freeradbiomed.2019.01.001

10. Kim SL, Choi HS, Kim JH, Jeong DK, Kim KS and Lee DS: Dihydrorytanshinone-induced NOX5 activation inhibits breast cancer stem cell through the ROS/STAT3 signaling pathway. Oxid Med Cell Longev 2019: 9296439, 2019. PMID: 9296439. DOI: 10.1155/2019/9296439

11. Khan NM, Ahmad I, Ansari MY and Haqqi TM: Wogonin, a natural flavonoid, intercalates with genomic DNA and exhibits protective effects in IL-1beta stimulated osteoarthritides chondrocytes. Chem Biol Interact 274: 13-23, 2017. PMID: 28688942. DOI: 10.1016/j.cbi.2017.06.025

12. Xing F, Sun C, Luo N, He Y, Chen M, Ding S, Liu C, Feng L and Cheng Z: Wogonin increases cisplatin sensitivity in ovarian cancer cells through inhibition of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Med Sci Monit 25: 6007-6014, 2019. PMID: 31402794. DOI: 10.12659/MSM.913829

13. Huynh DL, Kwon T, Zhang JJ, Sharma N, Gera M, Ghosh M, Kim N, Kim Cho S, Lee DS, Park YH and Jeong DK: Wogonin suppresses stem cell-like traits of CD133-positive osteosarcoma cell via inhibiting metalloproteinase-9 expression. BMC Complement Altern Med. 17(1): 304, 2017. PMID: 28606135. DOI: 10.1186/s12906-017-1788-y

14. Chandimiali N, Sun HN, Kong LZ, Zhen X, Liu R, Kwon T, Kim TD and Lee DS: Shikonin-induced apoptosis of colon cancer cells is reduced by peroxiredoxin V expression. Anticancer Res 39(11): 6115-6123, 2019. PMID: 28688942. DOI:10.21873/anticancer.13819

15. Chandimiali N, Jeong DK and Kwon T: Peroxiredoxin II regulates cancer stem cells and stemness-associated properties of cancers. Cancers 10(9): 305, 2018. PMID: 30177619. DOI: 10.3390/cancers10090305

16. Kim MH, Seong JB, Huh JW, Bae YC, Lee HS and Lee DS: Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling. Redox Biol 28: 101315, 2019. PMID: 31505325. DOI: 10.1016/j.redox.2019.101315

17. Tang T, Wang S, Cai T, Cheng Z, Qi S and Qi Z: Calenduloside E inhibits lipopolysaccharide-induced inflammatory response by inhibiting activation of ROS-mediated JAK1-STAT3 signaling pathway in Raw264.7 cells. Nan Fang Yi Ke Da Xue Xue Bao 39(8): 904-910, 2019 (in Chinese). PMID: 31511209. DOI: 10.12122/j.issn.1673-4254.2019.08.05

18. Xie C, Yi J, Lu J, Nie M, Huang M, Rong J, Zhu Z, Chen J, Zhou X, Li B, Chen H, Lu N and Shu X: N-Acetylcysteyline reduces ROS-mediated oxidative DNA damage and PI3K/AKT pathway activation induced by Helicobacter pylori infection. Oxid Med Cell Longev 2018: 1874985, 2018. PMID: 29854076. DOI: 0.1155/2018/1874985
21 Kim MH, Park SJ, Seong JB, Kim KM, Woo HA and Lee DS: Peroxiredoxin 5 regulates adipogenesis-attenuating oxidative stress in obese mouse models induced by a high-fat diet. Free Radic Biol Med 123: 27-38, 2018. PMID: 29777756. DOI: 10.1016/j.freeradbiomed.2018.05.061
22 Wang Z, Shen J, Sun W, Zhang T, Zuo D, Wang H, Wang G, Xu J, Yin F, Mao M, Zhou Z, Hua Y and Cai Z: Antitumor activity of raddeanin a is mediated by JUN amino-terminal kinase activation and signal transducer and activator of transcription 3 inhibition in human osteosarcoma. Cancer Sci 110(5): 1746-1759, 2019. PMID: 30907478. DOI: 10.1111/cas.14008
23 Kim JH, Choi HS, Kim SL and Lee DS: The PAK1-STAT3 signaling pathway activates IL-6 gene transcription and human breast cancer stem cell formation. Cancers 11(10): 1527, 2019. PMID: 31658701. DOI: 10.3390/cancers11101527
24 Zhang T, Li J, Yin F, Lin B, Wang Z, Xu J, Wang H, Zuo D, Wang G, Hua Y and Cai Z: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3. Oncogene 36(47): 6627-6639, 2017. PMID: 28783167. DOI: 10.1038/onc.2017.270
25 Cai N, Zhou W, Ye LL, Chen J, Liang QN, Chang G and Chen JJ: The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res 9(8): 3853-3866, 2017. PMID: 28861175.
26 Kim B, Park J, Chang KT, Lee DS. Peroxiredoxin 5 prevents amyloid-beta oligomer-induced neuronal cell death by inhibiting ERK-DRP1-mediated mitochondrial fragmentation. Free Radic Biol Med. 90: 184-194, 2016. PMID: 26582373. DOI: 10.1016/j.freeradbiomed.2015.11.015
27 Wang Y, Sun HJ, Li RG, Wang XM, Cheng ZQ and Lou N: Reprogramming factors induce proliferation and inhibit apoptosis of melanoma cells by changing the expression of particular genes. Mol Med Rep 19(2): 967-973, 2019. PMID: 30569122. DOI: 10.3892/mmr.2018.9753

Received January 9, 2020
Revised January 27, 2020
Accepted January 29, 2020